WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA – Research Report) and Vigil ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript November 6, 2024 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

万达制药公司(NASDAQ: VNDA)在2024年第三季度经历了喜忧参半的表现,根据2024年第三季度财报电话会议的详细内容,公司总收入较去年同期略有下降。尽管公司面临仿制药竞争导致Hetlioz销售下降的挑战,但PONVORY的引入和Fanapt用于治疗I型双相情感障碍的推出带来了收入增长。虽然今年前九个月出现净亏损,但万达对未来保持乐观态度,上调了2024年的指引,并为新药申请和临床试验做准 ...

Vanda Pharmaceuticals Inc (VNDA) reports a 23% revenue increase in Q3 2024, driven by Fanapt sales, despite a net loss and ...

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Vanda (VNDA – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at $4.89. Duncan covers ...

英为财情Investing.com - Vanda Pharmaceuticals (NASDAQ: VNDA )星期三发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.09，总营收为$47.7M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$50.75M，每股收益为$-0 ...

Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash rangesFanapt® launch in bipolar I ...

China Universal Asset Management Co. Ltd. increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 64.0% in the third quarter, according to the company in its most recent ...

Fintel reports that on October 31, 2024, HC Wainwright & Co. initiated coverage of Vanda Pharmaceuticals (NasdaqGM:VNDA) with ...

("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and ...